search
Back to results

Effects of Sitagliptin on Gastric Emptying in Healthy Subjects

Primary Purpose

Gastroparesis, Diabetes Mellitus

Status
Completed
Phase
Phase 1
Locations
Australia
Study Type
Interventional
Intervention
Sitagliptin
Placebo
Sponsored by
Royal Adelaide Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastroparesis focused on measuring gastric emptying, glycemia, appetite, incretin hormones

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Male or female (females must be using an appropriate contraceptive method)
  • 18 - 45 years
  • Body mass index (BMI) 19 - 25 kg/m2.

Exclusion criteria:

  • Subjects with gastrointestinal disease, history of gastrointestinal surgery and/or significant gastrointestinal symptoms
  • Subjects taking medication known to influence gastrointestinal function
  • Alcohol intake > 20 g per day
  • Smoking > 10 cigarettes per day
  • Pregnant and/or lactating females
  • Calculated creatinine clearance < 60 ml/min
  • Exposure to ionising radiation for research purposes in the previous 12 months.

Sites / Locations

  • Discipline of Medicine, Royal Adelaide Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Sitagliptin (100mg)

Placebo (sugar pill)

Arm Description

Active drug (sitagliptin)

Inactive drug (placebo)

Outcomes

Primary Outcome Measures

Gastric emptying rate

Secondary Outcome Measures

Intragastric distribution, gastrointestinal hormone release (GLP-1, GIP), glycemia, insulinemia, appetite

Full Information

First Posted
July 13, 2007
Last Updated
October 27, 2015
Sponsor
Royal Adelaide Hospital
Collaborators
Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00501657
Brief Title
Effects of Sitagliptin on Gastric Emptying in Healthy Subjects
Official Title
Effects of Sitagliptin on Gastric Emptying in Healthy Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
December 2014
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
December 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Royal Adelaide Hospital
Collaborators
Merck Sharp & Dohme LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine the effects of the drug, sitagliptin, on the rate at which the stomach empties, and the release of gut hormones and blood glucose concentrations, after a mashed potato meal in healthy subjects. Sitagliptin has been shown to reduce the blood glucose (sugar) response to a meal and this may potentially be due to slowing of stomach emptying. This is particularly relevant to people who have diabetes, in whom normalization of elevated blood glucose levels is important to maintain health.
Detailed Description
The purpose of this study is to evaluate the effect of sitagliptin on gastric emptying, intragastric meal distribution, postprandial glycemia and insulinemia in healthy subjects. Glucagon-like peptide-1 (GLP-1) inhibits gastric emptying, thereby slowing the delivery of nutrients, and their absorption, across the small intestine. The rate of entry of carbohydrate into the small intestine is especially important in patients with diabetes mellitus. Sitagliptin is an orally administered inhibitor of dipeptidyl-peptidase-IV (DPP-IV), the enzyme responsible for the degradation of GLP-1. It is hypothesized that sitagliptin will increase the GLP-1 response to, and thereby slow gastric emptying and diminish the glycemic response to, a carbohydrate-containing meal. Fifteen healthy subjects (male and female) will be studied. Each subject will be studied on two occasions following treatment for 2 days with sitagliptin (100mg once daily) or matching placebo in a randomized, double blind, crossover design. Measurements of gastric emptying, intragastric meal distribution, blood glucose concentrations, gut hormones and appetite will be measured for 4 hours following ingestion of a mashed potato meal.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroparesis, Diabetes Mellitus
Keywords
gastric emptying, glycemia, appetite, incretin hormones

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sitagliptin (100mg)
Arm Type
Experimental
Arm Description
Active drug (sitagliptin)
Arm Title
Placebo (sugar pill)
Arm Type
Placebo Comparator
Arm Description
Inactive drug (placebo)
Intervention Type
Drug
Intervention Name(s)
Sitagliptin
Other Intervention Name(s)
MK-0431-075, Januvia
Intervention Description
100mg mane for 2 days
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
100mg mane for 2 days
Primary Outcome Measure Information:
Title
Gastric emptying rate
Time Frame
4 hours per study
Secondary Outcome Measure Information:
Title
Intragastric distribution, gastrointestinal hormone release (GLP-1, GIP), glycemia, insulinemia, appetite
Time Frame
4 hours per study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or female (females must be using an appropriate contraceptive method) 18 - 45 years Body mass index (BMI) 19 - 25 kg/m2. Exclusion criteria: Subjects with gastrointestinal disease, history of gastrointestinal surgery and/or significant gastrointestinal symptoms Subjects taking medication known to influence gastrointestinal function Alcohol intake > 20 g per day Smoking > 10 cigarettes per day Pregnant and/or lactating females Calculated creatinine clearance < 60 ml/min Exposure to ionising radiation for research purposes in the previous 12 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karen L Jones, PhD
Organizational Affiliation
University of Adelaide, Royal Adelaide Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Discipline of Medicine, Royal Adelaide Hospital
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia

12. IPD Sharing Statement

Citations:
PubMed Identifier
22738299
Citation
Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study. Aliment Pharmacol Ther. 2012 Aug;36(4):379-90. doi: 10.1111/j.1365-2036.2012.05198.x. Epub 2012 Jun 28.
Results Reference
derived
Links:
URL
http://www.ncbi.nlm.nih.gov/pubmed/22738299
Description
Pubmed abstract

Learn more about this trial

Effects of Sitagliptin on Gastric Emptying in Healthy Subjects

We'll reach out to this number within 24 hrs